Handelsbanken Fonder AB Buys 450,000 Shares of Cellebrite DI Ltd. $CLBT

Handelsbanken Fonder AB lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,900,000 shares of the company’s stock after acquiring an additional 450,000 shares during the period. Handelsbanken Fonder AB owned approximately 1.21% of Cellebrite DI worth $53,737,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Venturi Wealth Management LLC increased its holdings in Cellebrite DI by 5.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock worth $272,000 after purchasing an additional 700 shares in the last quarter. CWM LLC boosted its position in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after buying an additional 720 shares during the period. Blue Trust Inc. boosted its position in shares of Cellebrite DI by 4.0% during the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after buying an additional 898 shares during the period. SkyView Investment Advisors LLC grew its holdings in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after buying an additional 970 shares in the last quarter. Finally, Fox Run Management L.L.C. raised its position in Cellebrite DI by 3.9% in the 2nd quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock valued at $486,000 after buying an additional 1,127 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $13.34 on Friday. The company has a fifty day moving average price of $16.05 and a two-hundred day moving average price of $16.96. Cellebrite DI Ltd. has a one year low of $11.76 and a one year high of $20.86. The stock has a market cap of $3.19 billion, a P/E ratio of 43.03, a P/E/G ratio of 2.11 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The company had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same period in the prior year, the firm earned $0.10 EPS. Cellebrite DI’s quarterly revenue was up 28.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CLBT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Needham & Company LLC cut their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.